Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Oppenheimer reiterated their outperform rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $9.00 target price on the stock. Separately, Needham & Company LLC reaffirmed a buy rating and set a $8.00 price target on shares of Trevi Therapeutics in […]
Trevi Therapeutics to Participate in Upcoming March Events marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Silverarc Capital Management LLC lifted its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 4.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 927,415 shares of the company’s stock after acquiring an additional 41,491 shares during the […]